KR880701102A - 주석 디요오도 듀테로 포르피린의 치료용도 - Google Patents
주석 디요오도 듀테로 포르피린의 치료용도Info
- Publication number
- KR880701102A KR880701102A KR1019880700191A KR880700191A KR880701102A KR 880701102 A KR880701102 A KR 880701102A KR 1019880700191 A KR1019880700191 A KR 1019880700191A KR 880700191 A KR880700191 A KR 880700191A KR 880701102 A KR880701102 A KR 880701102A
- Authority
- KR
- South Korea
- Prior art keywords
- increase
- heme
- tin
- rate
- requirement
- Prior art date
Links
- BUNNSNWDQSGONB-KXUUBAJSSA-N IN1C=2C=CC1=CC=1C=CC(=CC3=CC(=C(N3I)C=C3C=CC(C2)=N3)[2H])N1.[Sn] Chemical compound IN1C=2C=CC1=CC=1C=CC(=CC3=CC(=C(N3I)C=C3C=CC(C2)=N3)[2H])N1.[Sn] BUNNSNWDQSGONB-KXUUBAJSSA-N 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 12
- 150000003278 haem Chemical class 0.000 claims 11
- 230000029142 excretion Effects 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 4
- 238000007911 parenteral administration Methods 0.000 claims 4
- 230000004060 metabolic process Effects 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000037323 metabolic rate Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2204—Not belonging to the groups C07F7/2208 - C07F7/2296
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (15)
- 주석 디요오도듀테로포르피린.
- 주석 디요오도듀테로포르피린과 제약상 허용되는 담체로 되는 비경구 투여용 제약 조성물.
- 제약상 허용되는 담체 중에서 농도 0.5μmol/ml 내지 25μmol/ml의 주석 디요오도듀테로포르피린으로 되는 투여 단위 형태의 비경구 투여용 제약 조성물.
- 헴 대사율을 감소시키기에 유효한 양의 주석 디요오도듀테로포르피린을 포유동물에 투여함으로써 이러한 치료가 요구되는 포위동물에서 핵 대사율을 감소시키는 방법
- 제4항에 있어서, 포유 동물이 인체인 방법.
- 헴 대사율을 증가시키기에 충분한 양의 주석 디요오도듀테로포르피린을 비경구 투여하는 것으로 되는, 이와 같은 헴 배출의 증가가 요구되는 포유동물에 의해 헴이 배출되는 속도를 증가시키는 방법.
- 제6항에 있어서, 포유 동물이 인체인 방법.
- 제6항에 있어서, 헴 배출율의 증가에 대한 요구가 급성 또는 만성 용혈 현상인 방법.
- 제6항에 있어서, 헴 베출율의 증가에 대한 요구가, 주의의 불리한 화학물질 또는 영향에 노출됨으로 인한 적세포 붕괴인 방법.
- 제6항에 있어서, 헴 배출율의 증가에 대한 요구가 과도한 헴의 투여로 인한 것인 방법.
- 제6항에 있어서, 헴 배출율의 증가에 대한 요구가 급성 철 중독인 방법.
- 제6항에 있어서, 헴 배출율의 증가에 대한 요구가 만성 철 과부하인 방법.
- 제6항에 있어서, 헴 배출율의 증가에 대한 요구가 해양빈혈인 방법.
- 제6항에 있어서, 헴 배출율의 증가에 대한 요구가 겸상 적혈구 빈혈증인 방법
- 트립토판 대사율을 증가시키기에 유효한 양의 주석 디요오도듀테로포르피린을 비경구 투여하는 것으로 되는, 이와 같은 증가가 요구되는 인체의 간에서 트립토판 대사율을 증가시키는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US876921 | 1986-06-20 | ||
| US06/876,921 US4668670A (en) | 1986-06-20 | 1986-06-20 | Tin diiododeuteroporphyrin and therapeutic use thereof |
| US008869 | 1987-01-29 | ||
| US06/008,869 US4692439A (en) | 1986-06-20 | 1987-01-29 | Therapeutic use of tin diiododeuteroporphyrin |
| PCT/US1987/000939 WO1987007837A1 (en) | 1986-06-20 | 1987-04-21 | Therapeutic use of tin diiododeuteroporphyrin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR880701102A true KR880701102A (ko) | 1988-07-25 |
Family
ID=26678723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019880700191A KR880701102A (ko) | 1986-06-20 | 1987-04-21 | 주석 디요오도 듀테로 포르피린의 치료용도 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4692439A (ko) |
| KR (1) | KR880701102A (ko) |
| AU (1) | AU595047B2 (ko) |
| DK (1) | DK87888D0 (ko) |
| PH (1) | PH24632A (ko) |
| WO (1) | WO1987007837A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4782049A (en) * | 1986-12-08 | 1988-11-01 | The Rockefeller University | Tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis |
| KR890701108A (ko) * | 1987-09-08 | 1989-12-19 | 원본미기재 | 종양요법의 독성효과를 반전시키기 위한 메탈로포르피린의 사용 |
| US5010073A (en) * | 1989-10-05 | 1991-04-23 | The Rockefeller University | Use of liposomes as carriers for metalloporphyrins |
| WO2000017226A1 (en) * | 1998-09-23 | 2000-03-30 | The Regents Of The University Of California | Synthetic peptides, conjugation reagents and methods |
| US7375216B2 (en) * | 2002-06-04 | 2008-05-20 | Infacare Pharmaceutical Corporation | Preparation of metal mesoporphyrin compounds |
| US20060222668A1 (en) * | 2005-04-01 | 2006-10-05 | Wellspring Pharmaceutical Corporation | Stannsoporfin compositions, drug products and methods of manufacture |
| MX345035B (es) | 2006-10-04 | 2017-01-16 | Infacare Pharmaceutical Corp | Preparación a gran escala y alta pureza de estansoporfina. |
| HUE032290T2 (en) | 2011-03-30 | 2017-09-28 | Infacare Pharmaceutical Corp | Methods for producing metal mesoporphyrins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0084053B1 (en) * | 1981-07-15 | 1987-09-09 | The Rockefeller University | Pharmaceutical composition and the use of sn- or cr-protoporphyrin for the manufacture thereof |
| US4619923A (en) * | 1985-01-14 | 1986-10-28 | The Rockefeller University | Metal protoporphyrins in the control of tryptophan metabolism |
-
1987
- 1987-01-29 US US06/008,869 patent/US4692439A/en not_active Expired - Lifetime
- 1987-04-21 AU AU74812/87A patent/AU595047B2/en not_active Ceased
- 1987-04-21 WO PCT/US1987/000939 patent/WO1987007837A1/en unknown
- 1987-04-21 KR KR1019880700191A patent/KR880701102A/ko not_active Application Discontinuation
- 1987-05-08 PH PH35244A patent/PH24632A/en unknown
-
1988
- 1988-02-19 DK DK087888A patent/DK87888D0/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US4692439A (en) | 1987-09-08 |
| WO1987007837A1 (en) | 1987-12-30 |
| DK87888A (da) | 1988-02-19 |
| DK87888D0 (da) | 1988-02-19 |
| PH24632A (en) | 1990-08-17 |
| AU7481287A (en) | 1988-01-12 |
| AU595047B2 (en) | 1990-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Crosby | The rationale for treating iron deficiency anemia | |
| Cohen | Management of iron overload in the pediatric patient | |
| KR960000219A (ko) | 당뇨병 합병증 치료용 조성물 | |
| KR920002144A (ko) | 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제 | |
| KR880701102A (ko) | 주석 디요오도 듀테로 포르피린의 치료용도 | |
| KR850700109A (ko) | 항 이뇨제 ddavp 및 그의 제조 방법 | |
| Rehman et al. | Proabsorptive action of gum arabic: regulation of nitric oxide metabolism in the basolateral potassium channel of the small intestine | |
| KR920019350A (ko) | 자기면역질환요법을 위한 약제조성물 | |
| Wyon et al. | Vecuronium-induced depression of phrenic nerve activity during hypoxia in the rabbit | |
| KR920702225A (ko) | 약학 조성물 | |
| JPS57126420A (en) | Drug for digestive organ | |
| KR910000130A (ko) | 진경제 | |
| ES2164703T3 (es) | Metodo para el tratamiento de la enfermedad neoplasica utilizando la tiazofurina y la ribavirina. | |
| FR2373287A1 (fr) | Nouvelle association de principes actifs de medicaments pour maitriser de facon selective les reactions immunitaires induites chez un hote par l'administration d'antigenes | |
| JPS5551019A (en) | Drug containing alllee or 133zz7*88dehydroo retine acid and manufacture thereof | |
| KR910700263A (ko) | 시클로리노펩티드를 포함하는 의약 | |
| KR830009776A (ko) | 세포 보호 유도방법 | |
| Hargreaves et al. | Studies on the effects of l-ascorbic acid on acetaminophen-induced hepatotoxicity: II. An in vivo assessment in mice of the protection afforded by various dosage forms of ascorbate | |
| Takahashi et al. | Use of pyridoxine-5-thiol in methyl mercury poisoning | |
| Saidman et al. | Uptake and distribution of thiopental after oral, rectal, and intramuscular administration: Effect of hepatic metabolism and injection site blood flow | |
| Muñiz et al. | Unsuspected acetaminophen toxicity in a 58-day-old infant | |
| Weinberg | Evidence that melatonin retention by the neonatal rat is greatly increased as compared to the adult: a novel biochemical mechanism | |
| RG | ROLE OF Cat+ IN METABOLIC ACTIONS OF DRUGS IN INTESTINAL | |
| FR2744917A1 (fr) | Composition therapeutique a base d'acetaminophene | |
| KR900017599A (ko) | 종양 치료용 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |